However, in a sign of subdued market sentiment, the grey market premium (GMP) for the Aakaar IPO stands at Rs 0. This implies that the stock is expected to list at par, with no immediate listing gain or loss anticipated.
The company, incorporated in 2013, offers a wide portfolio of aesthetic medical devices and dermatological products, catering to cosmetic surgeons, dermatologists, and aesthetic physicians across India.
With a presence in over a dozen states and a robust distribution network, Aakaar has grown its revenue by 33% year-on-year, reaching Rs 61.76 crore in FY25. Net profit surged by 110% to Rs 6.04 crore, reflecting operational efficiency and expansion in high-margin product lines.
The IPO proceeds are primarily earmarked for working capital requirements and general corporate purposes.
Live Events
Aakaar Medical Technologies enters the market with a strong financial base but muted listing sentiment. Market watchers will be keeping a close eye on whether post-listing momentum picks up amid broader SME investor appetite.(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)
